(Q26991744)

Greg Irving

series ordinal

2

1 reference

Steven Todd Wiersma

series ordinal

3

1 reference

language of work or name

1 reference

17 December 2012

1 reference

number of pages

9

1 reference

based on heuristic

inferred from page(s)

1 reference

31

1 reference

issue

1

1 reference

page(s)

3-11

1 reference

Hepatitis A virus seroprevalence by age and world region, 1990 and 2005.

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.104

A controlled trial of a formalin-inactivated hepatitis A vaccine in healthy children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.104

Hepatitis A vaccine: indirect evidence of immune memory 12 years after the primary course.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.104

Inactivated hepatitis A vaccine: long-term antibody persistence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.104

Predicted 30-year protection after vaccination with an aluminum-free virosomal hepatitis A vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.104

Hepatitis A booster vaccination: is there a need?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.104

Excellent booster response 4-6 y after a single primary dose of an inactivated hepatitis A vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.104

Inactivated hepatitis A vaccine booster given >/=24 months after the primary dose

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.104

Hepatitis A virus-specific humoral and cellular immune responses following immunization with a formalin-inactivated hepatitis A vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.104

Long-term follow-up of hepatitis A vaccination in children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.104

Follow-up immunogenicity of an inactivated hepatitis A virus vaccine in healthy children: results after 5 years

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.104

Long-term persistence of anti-HAV antibodies following active immunization with hepatitis A vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.104

Hepatitis A vaccine: persistence of antibodies 5 years after the first vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.104

Interchangeability and tolerability of a virosomal and an aluminum-adsorbed hepatitis A vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.104

Long-term durability of immune responses after hepatitis A vaccination among HIV-infected adults.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.104

Long-term clinical observation of the immunogenicity of inactivated hepatitis A vaccine in children.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.104

Long-term immunogenicity after single and booster dose of a live attenuated hepatitis A vaccine: results from 8-year follow-up

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.104

Long-term persistence of humoral immunity after hepatitis A vaccination in HIV-infected adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.104

Publishing research from developing countries

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.104

Inactivated hepatitis A vaccine: active and passive immunoprophylaxis in chimpanzees

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.104

Serum Neutralizing Antibody Response to Hepatitis A Virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.104

Cost-effectiveness of childhood hepatitis A vaccination in Argentina: a second dose is warranted.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.104

The economics of routine childhood hepatitis A immunization in the United States: the impact of herd immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.104